{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T06:35:21Z","timestamp":1778999721019,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.msard.2025.106284","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T08:11:30Z","timestamp":1738138290000},"page":"106284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection"],"prefix":"10.1016","volume":"95","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fereshteh","family":"Ashtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahid Beladi","family":"Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Poursadeghfard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzie","family":"Abutorabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Nahayati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sareh","family":"Shahmohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Ebadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hora","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3224-8807","authenticated-orcid":false,"given":"Mohammad Ali","family":"Sahraian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106284_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-zoster virus infections in patients treated with Fingolimod","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.msard.2025.106284_bib0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.14218\/ERHM.2023.00053","article-title":"Cancers associated with Human papillomavirus: an overview of prevalence in Iran and the Middle East","volume":"9","author":"Baghi","year":"2024","journal-title":"Explor. Res. Hypothesis Med."},{"key":"10.1016\/j.msard.2025.106284_bib0003","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106284_bib0004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/v13020321","article-title":"Persistent Human papillomavirus infection","volume":"13","author":"Della Fera","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2025.106284_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001156","article-title":"Cryptococcal meningitis reported with fingolimod treatment","volume":"9","author":"Del Poeta","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106284_bib0006","first-page":"28","article-title":"HPV-associated anal and genital intraepithelial neoplasia after using Fingolimod in the treatment of relapsing-remitting multiple sclerosis: a case report","volume":"2","author":"Doganay Ocalan","year":"2022","journal-title":"J. Mult. Scler. Res."},{"key":"10.1016\/j.msard.2025.106284_bib0007","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2025.106284_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/v9100267","article-title":"Natural history of HPV infection across the lifespan: role of viral latency","volume":"9","author":"Gravitt","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2025.106284_bib0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/08830185.2020.1811859","article-title":"Immunology of HPV-mediated cervical cancer: current understanding","volume":"40","author":"Jee","year":"2021","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106284_bib0010","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-19-3211","article-title":"B cells improve overall survival in HPV-associated squamous cell carcinomas and are activated by radiation and PD-1 blockade","volume":"26","author":"Kim","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.msard.2025.106284_bib0011","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458518813109","article-title":"Clinical commentary on \u201cwarts and all: fingolimod and unusual HPV associated lesions","volume":"25","author":"Macaron","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106284_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15171\/ijhpm.2015.201","article-title":"Priority setting for improvement of cervical cancer prevention in Iran","volume":"5","author":"Majidi","year":"2015","journal-title":"Int. J. Heal. Policy Manag."},{"key":"10.1016\/j.msard.2025.106284_bib0013","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1177\/1352458521991433","article-title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination","volume":"27","author":"Mhanna","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106284_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.30699\/IJP.2019.90356.1861","article-title":"The prevalence of HPV genotypes in Iranian population: an update","volume":"14","author":"Mobini Kesheh","year":"2019","journal-title":"Iran. J. Pathol."},{"key":"10.1016\/j.msard.2025.106284_bib0015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/CON.0000000000001156","article-title":"Diagnosis of multiple sclerosis","volume":"28","author":"Oh","year":"2022","journal-title":"Contin. Lifelong Learn. Neurol."},{"key":"10.1016\/j.msard.2025.106284_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001183","article-title":"Transitioning from S1P receptor modulators to B cell\u2013Depleting therapies in multiple sclerosis","volume":"9","author":"Rowles","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2025.106284_bib0017","doi-asserted-by":"crossref","first-page":"489","DOI":"10.54029\/2024kps","article-title":"Ocrelizumab experience in treatment-resistant warts associated with Fingolimod: a case report","volume":"29","author":"Uca","year":"2024","journal-title":"Neurol. Asia"},{"key":"10.1016\/j.msard.2025.106284_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106284_bib0019","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T04:48:30Z","timestamp":1741841310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"alternative-id":["S2211034825000288"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106284","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106284"}}